Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 16, 2008. The report details a specific corporate action regarding share repurchases and cancellations authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
- Shares Purchased: 2,625,000 Ordinary shares.
- Purchase Price: 1,082.81 pence per share.
- Treasury Shares Cancelled: 10,000,000 Ordinary shares.
- Remaining Treasury Shares: 474,194,158 shares (representing 8.92% of total voting rights).
- Shares in Issue: 5,317,781,367 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of newly purchased shares and existing Treasury shares. Consequently, the total number of shares in issue remains 5,317,781,367, while the proportion of Treasury shares held by the company now represents 8.92% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,317,781,367) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on the total voting rights percentage (8.92%).
- Note that the 2,625,000 shares purchased on June 16, 2008, were immediately cancelled and are no longer part of the Treasury holding.